Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HPC16+
- Development stage
- Preclinical
- Lead developer
- etherna
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
HPC16+ is an mRNA-based therapeutic cancer vaccine being developed by eTheRNA immunotherapies. The vaccine utilizes lipid nanoparticle (LNP) technology to deliver mRNA encoding the E6 and E7 oncoproteins of Human Papillomavirus type 16 (HPV16). Designed for intravenous administration, HPC16+ aims to induce a robust, antigen-specific immune response by activating cytotoxic T lymphocytes (CTLs) that can recognize and destroy HPV16-positive tumor cells. The program is currently in preclinical development for the treatment of HPV16-associated malignancies, including cervical, head and neck, and anogenital cancers, and is intended for use as both a standalone therapy and in combination with PD-1 inhibitor checkpoint blockades.
- Other names
- eTheRNA HPV16 mRNA vaccineHPV16 mRNA-LNP vaccineHPV-16 mRNA-LNP vaccineHPV 16 mRNA-LNP vaccine
02
Targets
HPV16 E7 (Human papillomavirus 16 E7 protein)HPV16 E6 oncoprotein
Beyond the preview
Go deeper on HPC16+.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HPC16+.